What to Do With a Mildly Elevated SDMA: A Decision Guide for Busy Practitioners
You run a wellness panel on a clinically healthy canine adult patient. Everything looks normal except for one number: SDMA comes back at 16 µg/dL. Creatinine is comfortably midrange. The dog appears healthy and the pet parent is happy. What do you do with that result?
If you have ever paused in that moment, you are in good company. Mildly increased SDMA results can be common and create some uncertainty. This is a guide for moving forward with confidence when the number lands just above that normal range.
Practical Takeaways
A mild elevation is a flag, not a diagnosis—treat it as the start of a client conversation, not the end of one.
Pair SDMA with urinalysis and other evidence of decreased globular filtration rate before a diagnosis or treatment plan is made and communicated.
A recheck in two to four weeks provides more information on persistence.
Considering the whole patient and trending values over time is more accurate than a single measurement.
Structured follow-up is what makes your care consistent from patient to patient and from veterinarian to veterinarian in each practice.
Why This Matters Now
Mild SDMA elevations are not edge cases. Results in the 15 to 19 µg/dL range make up 57% of all increased SDMA concentrations reported by IDEXX Reference Laboratories. In other words, the borderline result is more typical.
What makes these cases tricky is that creatinine often looks completely within normal range. In an IDEXX study of nearly 33,000 cats and dogs, 81% of patients with a mild SDMA elevation that persisted had creatinine within the reference interval when SDMA first increased. SDMA can rise with as little as 25% loss of kidney function, earlier than creatinine tends to move. That early signal is exactly why a borderline number deserves a second look rather than a shrug.
When we lack a consistent approach, two things tend to happen. Some of us overemphasize the result and worry the pet parent. Others casually note it and move on. A simple, repeatable framework will take the guesswork out of that decision.
When To Consider This Approach
This is guidance for the clinically stable patient, not the crashing one. Reach for this approach when you see:
A mild or borderline SDMA elevation, roughly 15 to 19 µg/dL
A non-azotemic patient with creatinine still in range
No obvious acute illness that explains the change
A first-time or newly identified elevation
This is not meant to guide decisions with an emergent patient. Instead, the goal is a proportional response, meaning enough investigation to understand the result without overreacting to a single value.
What the Evidence Says
SDMA reflects glomerular filtration rate (GFR), so a mild increase points to mildly reduced GFR. The real question is whether that change is transient or the start of something more permanent.
After a single mildly increased SDMA, there is a 72% probability of another increased SDMA within one year. Put differently, a borderline result today is far more likely to repeat than to resolve and disappear. These patients carried more than five times the risk of an increased result on the next test compared with patients whose SDMA was in range.
The creatinine story follows close behind. Among patients whose mild SDMA elevation persisted, the share with concurrently increased creatinine climbed from 19% at the start to 48% by one year. SDMA most often moved first. That is the early warning sign sitting inside a single borderline number.
One more practical point to consider. Only 16% of mild elevations in that study were rechecked within a month. The opportunity to catch these patients early is real, and most of us aren't closing this recheck gap.
A Simple Path To Follow
The IDEXX SDMA algorithm lays out a clear path for clinicians. For a mild elevation in a stable patient, it looks like this:
Confirm the mild elevation. SDMA above 14 µg/dL is increased. For puppies, an SDMA above 16 µg/dL is increased.
Run a complete urinalysis. Urine-specific gravity (USG), sediment, and protein add the needed context a single chemistry value cannot give you.
Look for other evidence of decreased GFR. Check for creatinine increasing within the reference interval, elevated BUN or phosphorus, inappropriate urine-specific gravity, active sediment, proteinuria, polyuria/polydipsia, weight loss, abnormal kidney palpation or imaging, and/or hypertension.
Recheck the kidney panel in two to four weeks if clinically appropriate, or at minimum, SDMA, BUN, creatinine, phosphorus, and urinalysis.
Use the trend, not the single number, to guide what comes next.
If the recheck shows SDMA has returned to a normal range, you may be seeing recovery from a mild insult, a response to therapy, or compensatory mechanisms at work. If SDMA stays increased but stable, consider early chronic kidney disease and follow IRIS staging and treatment guidelines. If it continues to climb, treat it as ongoing kidney injury and investigate further.
The reason the recheck matters so much comes back to persistence. A mild elevation that repeats is your signal for action, and the recheck is how you separate the transient from the persistent before creatinine ever catches up.
The Bottom Line
A borderline SDMA does not have to be a source of uncertainty. With a simple, stepwise approach (confirm the result, add a urinalysis, look for supporting evidence, recheck, and follow the trend), you can move forward with confidence.
